Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of STAR-0310 in Healthy Adult Participants
Sponsor: Astria Therapeutics, Inc.
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose trial evaluating the safety, tolerability, PK, and immunogenicity of STAR-0310 in healthy adult participants. There are 4 planned cohorts and potentially up to 1 additional cohort which may comprise of healthy adult participants of Japanese descent.
Official title: A First-in-Human, Phase 1a, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STAR-0310 in Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-01-07
Completion Date
2026-01
Last Updated
2025-11-04
Healthy Volunteers
Yes
Conditions
Interventions
STAR-0310
STAR-0310 will be administered as a subcutaneous bolus injection.
Placebo
Placebo will be administered as a subcutaneous bolus injection.
Locations (1)
Austin Clinical Research Unit - Early Clinical Development
Austin, Texas, United States